Brokerages Set Fractyl Health, Inc. (NASDAQ:GUTS) PT at $5.12

Fractyl Health, Inc. (NASDAQ:GUTS) has been given a consensus recommendation of “Hold” by the five analysts that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $5.50.

Several brokerages have issued reports on GUTS. HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Fractyl Health in a research note on Thursday, June 4th. Wall Street Zen downgraded shares of Fractyl Health from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Craig Hallum assumed coverage on Fractyl Health in a report on Wednesday, July 1st. They issued a “buy” rating and a $4.00 price objective for the company. Finally, Weiss Ratings raised Fractyl Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 20th.

Insider Buying and Selling

In related news, Director Ian Sheffield purchased 35,000 shares of the firm’s stock in a transaction on Wednesday, June 10th. The stock was purchased at an average cost of $0.73 per share, for a total transaction of $25,550.00. Following the completion of the purchase, the director directly owned 35,000 shares in the company, valued at $25,550. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director William Bradley purchased 68,493 shares of the stock in a transaction on Wednesday, June 10th. The shares were bought at an average cost of $0.73 per share, for a total transaction of $49,999.89. Following the transaction, the director directly owned 84,622 shares in the company, valued at approximately $61,774.06. The trade was a 424.66% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders acquired 171,493 shares of company stock valued at $127,150. Corporate insiders own 8.52% of the company’s stock.

Institutional Trading of Fractyl Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in GUTS. Pale Fire Capital SE lifted its stake in Fractyl Health by 84.5% in the first quarter. Pale Fire Capital SE now owns 5,921,045 shares of the company’s stock valued at $2,711,000 after acquiring an additional 2,711,103 shares during the last quarter. Atom Investors LP acquired a new position in shares of Fractyl Health during the 4th quarter worth about $4,143,000. General Catalyst Group Management LLC bought a new stake in shares of Fractyl Health in the 2nd quarter valued at about $3,880,000. 683 Capital Management LLC raised its holdings in shares of Fractyl Health by 30.1% in the 4th quarter. 683 Capital Management LLC now owns 6,047,620 shares of the company’s stock valued at $13,305,000 after purchasing an additional 1,397,620 shares during the period. Finally, Bank of America Corp DE acquired a new stake in Fractyl Health in the 2nd quarter valued at about $4,791,000.

Fractyl Health Trading Down 11.2%

NASDAQ:GUTS opened at $0.66 on Monday. Fractyl Health has a twelve month low of $0.38 and a twelve month high of $2.44. The company has a quick ratio of 3.15, a current ratio of 3.15 and a debt-to-equity ratio of 1.41. The business has a 50 day moving average price of $0.75 and a two-hundred day moving average price of $0.66. The company has a market cap of $104.90 million, a P/E ratio of -0.75 and a beta of 2.32.

Fractyl Health (NASDAQ:GUTS) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. As a group, analysts expect that Fractyl Health will post -0.53 EPS for the current fiscal year.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.